Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab technology platform.
Abraxis BioScience said that it has granted exclusive marketing rights to Specialised Therapeutics for Abraxane in New Zealand.
Accordingly, Specialised Therapeutics said that after receiving reimbursement approval from Pharmac, the New Zealand pharmaceutical reimbursement authority for Abraxane it will start the distribution of the product throughout New Zealand.
Patrick Soon-Shiong, executive chairman of Abraxis, said: “In the US and Australia Abraxane has rapidly become the taxane treatment of choice in its approved indication. We are pleased to provide this new treatment option for women in New Zealand with metastatic breast cancer.”
Carlo Montagner, CEO of Specialised Therapeutics, said: “Abraxane offers a safer and more efficacious taxane therapy for New Zealand women with metastatic breast cancer. Discussions with Pharmac will commence shortly and we hope to make Abraxane available as soon as an agreement with Pharmac is reached.”